Research Publications and Resources
Resources developed through HealthInsight Oregon’s ongoing research studies of the use of Prescription Drug Monitoring Program (PDMP) data as a tool for clinical decision making and for reducing misuse, abuse, and diversion of prescription drugs.
Increasingly, health care providers are looking to PDMPs as a tool to help improve patient safety and the quality of care, while reducing prescription drug abuse. For example, the PDMP allows clinicians and pharmacists to monitor a patient’s prescription history for warning signs of potential drug abuse or safety issues, such as multiple prescribers or pharmacies, early refills, high doses, multiple controlled drugs, or risky co-prescriptions.
The resources listed below are associated with HealthInsight Oregon’s five-year study for the National Institute on Drug Abuse (NIDA), exploring how clinicians can use PDMP features and data to improve their decision making about prescribing and pain management.
As we develop new resources through our other research studies, we will post them on this page. Please revisit this page periodically for resource updates.
Deyo RA, Hallvik SE, Hildebran C, Marino M, Dexter E, Irvine JM, O’Kane N, Van Otterloo J, Wright DA, Leichtling G, Millet LM. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naïve Patients: A Statewide Retrospective Cohort Study. J Gen Intern Med. 2017 Jan;32(1):21-27. Abstract.
Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. Clinicians’ Use of Prescription Drug Monitoring Programs in Clinical Practice and Decision-Making. Pain Med. 2017 Jun 1;18(6):1063-1069. Abstract.
O’Kane N, Hallvik SE, Marino M, Van Otterloo J, Hildebran C, Leichtling G, Deyo RA. Preparing a prescription drug monitoring program data set for research purposes. Pharmacoepidemiol Drug Saf. 2016 Sep;25(9) 993-997. Abstract.
Hildebran C, Leichtling G, Irvine JM, Cohen DJ, Hallvik SE, Deyo RA. Clinical Styles and Practice Policies: Influence on Communication with Patients Regarding Prescription Drug Monitoring Program Data. Pain Med. 2016 Nov;17(11):2061-2066. Abstract.
Deyo RA, Irvine JM, Hallvik SE, Hildebran C, Beran T, Millet LM, Marino M. Leading a horse to water: Facilitating registration and use of a prescription drug monitoring program. Clin J Pain. 2014 Nov 7. (Epub ahead of print). Abstract.
Hildebran C, Cohen D, Irvine J, Beran T, Foley C, O’Kane N, Deyo R. How clinicians use prescription drug monitoring programs: A qualitative inquiry. Pain Med. 2014 Jul;15(7):1179-86. Abstract.
Irvine JM, Hallvik SE, Hildebran C, Marino M, Beran T, Deyo RA. Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. J Pain. 2014;15:747–755. Abstract.
Deyo RA, Irvine JM, Millet LM, Beran T, O'Kane N, Wright DA, McCarty D. Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions. Health Aff (Millwood). 2013 Mar;32(3):603-613. Abstract.
PresentationsWhen Prescribers Use PDMP Data: Opioid Prescribing Before and After PDMP Registration Research team presentation at National Rx Drug Abuse and Heroin Summit, March 28–31, 2016, Atlanta, Ga.
PDMP Track: Linking and Mapping PDMP Data Research team presentation at National Rx Drug Abuse and Heroin Summit, March 28–31, 2016, Atlanta, Ga.
Strategic Methodology for Drug Risk Metric Research Poster presentation at PDMP Researchers Forum, May 28–29, 2015, Washington, D.C.
Prescriber Use of the PDMP: A Statewide Survey and Multistate Focus Groups Research team presentation at Harold Rogers PDMP National Meeting, September 25–27, 2013, Washington, DC.
PDMPs as User-Friendly Clinical Decision Support Tools Research team presentation at National Rx Drug Abuse Summit, April 6–9, 2015, Atlanta, Ga.